Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

Autor Zhou, Qing, Wu, Yi-Long
Vydáno v J Glob Oncol (2016)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

Autor Su, Shan, Wu, Yi-Long
Vydáno v J Hematol Oncol (2017)

Immunotherapy in the Asiatic population: any differences from Caucasian population?

Autor Peng, Lunxi, Wu, Yi-Long
Vydáno v J Thorac Dis (2018)

Surgery in oligometastatic NSCLC patients in the targeted therapy era

Autor Zhang, Qi, Wu, Yi-Long
Vydáno v Lung Cancer Manag (2016)

Novel agents and strategies for overcoming EGFR TKIs resistance

Autor Niu, Fei-Yu, Wu, Yi-Long
Vydáno 2014

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

Autor Niu, Fei-Yu, Wu, Yi-Long
Vydáno v Onco Targets Ther (2015)

Insight into early-phase trials for lung cancer in the United States

Autor Yang, Jin-Ji, Wu, Yi-Long
Vydáno v Chin J Cancer (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 bloc...

Autor Wu, Si-Pei, Wu, Yi-Long
Vydáno v J Immunother Cancer (2015)

CSCO joins ESMO Open—Cancer Horizons

Autor Zielinski, Christoph C, Wu, Yi-Long
Vydáno v ESMO Open (2016)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

Autor Gou, Lan-Ying, Wu, Yi-Long
Vydáno v Lung Cancer (Auckl) (2014)

Misuse of Pirated Drugs: Why China? What Is Next?

Autor Sun, Hui-wen, Wu, Yi-Long
Vydáno v J Glob Oncol (2016)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Autor Liu, Si-Yang, Wu, Yi-Long
Vydáno v J Hematol Oncol (2017)

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

Autor Ke, E-E, Wu, Yi-Long
Vydáno v Ther Adv Respir Dis (2016)

Adjuvant TKIs: still an optimal choice

Autor Liu, Si-Yang, Wu, Yi-Long
Vydáno v J Thorac Dis (2018)

Personalized adjuvant treatment: go through the past to the future

Autor Liu, Si-Yang, Wu, Yi-Long
Vydáno v J Thorac Dis (2019)

Biomarker for personalized immunotherapy

Autor Liu, Si-Yang, Wu, Yi-Long
Vydáno v Transl Lung Cancer Res (2019)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial P...

Autor Tu, Hai-Yan, Wu, Yi-Long
Vydáno v Onco Targets Ther (2020)

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

Autor Xu, Chongrui, Zhou, Qing, Wu, Yi-long
Vydáno 2012

Special issue on personalized therapy in lung cancer

Autor Zhang, Na, Zhong, Wen-Zhao, Wu, Yi-Long
Vydáno v Transl Lung Cancer Res (2014)

Emerging challenges of advanced squamous cell lung cancer

Autor Zhang, Yi-Chen, Zhou, Qing, Wu, Yi-Long
Vydáno v ESMO Open (2017)